ArticlesThe poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
Introduction
Poly(ADP-ribose) polymerase (PARP) is a nuclear enzyme with dual roles in DNA repair and transcription regulation. PARP mediates DNA single-strand break repair through the base excision repair pathway. BRCA1 and BRCA2 proteins are crucial for homologous recombination—an accurate DNA double-strand break repair process. In the absence of BRCA and homologous recombination function, error-prone forms of DNA double-strand break repair predominate, which can increase a cell's mutational load and thereby lead to tumorigenesis. Although BRCA dysfunction promotes an oncogenic advantage, it also renders cancer cells reliant on base excision repair and hence susceptible to PARP inhibition.1, 2
Synthetic lethality is an association between two genes whereby defects in either gene are compatible with cell viability, but simultaneous defects in both genes result in cell death.1, 2 BRCA or homologous recombination has a synthetic lethal interaction with PARP. Therapeutic exploitation of this interaction via PARP inhibition in BRCA mutation carriers with cancer results in promising antitumour activity and has a favourable toxicity profile.2, 3, 4, 5, 6, 7 Broader clinical application of this synthetic lethality is the focus of continuing research; many sporadic (non-inherited) cancers (eg, prostate and high-grade serous ovarian cancers) harbour epigenetic and genetic disruption of genes that are crucial for the homologous recombination pathway, such as BRCA1, BRCA2, FANC, ATM, CHEK2, MRE11A, and RAD51.8, 9, 10, 11, 12, 13, 14, 15
Aside from its role in DNA damage response, PARP has been implicated in transcription regulation of the androgen receptor (AR) and rearranged erythroblast transformation-specific genes, such as ERG, ETV1, and FLI1.16, 17, 18 PARP inhibitors have antitumour activity in preclinical models of TMPRSS2-ERG rearranged prostate cancer and EWS-FLI1 rearranged Ewing's sarcoma.16, 17, 18 Additionally, PARP inhibitors suppress AR target-gene expression and tumour proliferation.19 Several studies are assessing PARP inhibitors in prostate cancer and sarcoma on the basis of this emerging therapeutic rationale (NCT01576172; NCT01682772; NCT01583543).
Niraparib (MK4827) is an orally bioavailable PARP-1 and PARP-2 inhibitor, with a half maximum inhibitory concentration (IC50) of 3·8 nmol/L for PARP-1 and 2·1 nmol/L for PARP-2.20 It inhibits tumour growth in models with loss of BRCA and PTEN function.21 We investigated the safety, tolerability, dose-limiting toxic effects (DLTs), maximum tolerated dose (MTD), and pharmacokinetic and pharmacodynamic profiles of niraparib. Additionally, we aimed to assess preliminary antitumour activity in carriers of BRCA1 and BRCA2 mutations and patients with high-grade serous ovarian cancer and prostate cancer.6, 9, 10, 11, 12, 13, 14, 15, 16, 22, 23
Section snippets
Participants
We undertook a two-part, phase 1 dose-escalation study of niraparib at the Royal Marsden NHS Foundation Trust (Sutton, UK), H Lee Moffitt Cancer Center and Research Institute (Tampa, FL, USA), and the University of Wisconsin Carbone Cancer Center (Madison, WI, USA). Eligible patients had advanced solid malignancies; were not suitable to receive any established treatments; were aged at least 18 years; had a life expectancy of at least 12 weeks; had an Eastern Cooperative Oncology Group
Results
Between Sept 15, 2008, and Jan 14, 2011, we enrolled 100 patients: 60 in part A and 40 in part B (figure 1). Table 1 shows patient characteristics. No major differences in participants or outcomes were reported across the three sites (data not shown).
569 cycles were administered (median per participant three [range one to 29]), at ten dose levels ranging from 30 mg/day to 400 mg/day (figure 1, table 2). Overall, four DLTs were recorded in the first cycle (table 2). At 30 mg/day, one of six
Discussion
We have shown that niraparib—an oral potent, selective PARP-1 and PARP-2 inhibitor—has favourable pharmacokinetics, inhibits PARP activity, is well tolerated up to the recommended phase 2 dose of 300 mg/day, and has antitumour activity in carriers of BRCA1 and BRCA2 mutations and patients with sporadic cancers. Non-haematological toxic effects were mild in severity and manageable. Grade 4 thrombocytopenia was dose limiting at 400 mg/day. In all cases, myelosuppression was self-limiting,
References (35)
- et al.
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Lancet
(2010) - et al.
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Lancet Oncol
(2011) - et al.
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Lancet
(2010) - et al.
Mutations in CHEK2 associated with prostate cancer risk
Am J Hum Genet
(2003) - et al.
FANCF methylation contributes to chemoselectivity in ovarian cancer
Cancer Cell
(2003) - et al.
The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo
Blood
(2010) - et al.
Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity
Eur Urol
(2013) - et al.
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer
Cancer Cell
(2011) - et al.
Dose-finding in phase I clinical trials based on toxicity probability intervals
Clin Trials
(2007) - et al.
Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer
Mod Pathol
(2012)
Poly(ADP-ribose) polymerase (PARP) inhibitors: exploiting a synthetic lethal strategy in the clinic
CA Cancer J Clin
The DNA damage response and cancer therapy
Nature
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers
N Engl J Med
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval
J Clin Oncol
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer
N Engl J Med
Integrated genomic analyses of ovarian carcinoma
Nature
Germline mutations in RAD51D confer susceptibility to ovarian cancer
Nat Genet
Cited by (467)
PARP Inhibitors in Metastatic Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis of Existing Evidence
2024, Clinical Genitourinary CancerDevelopment and validation of a sensitive LC–MS/MS method for the assay of four PARP inhibitors in human plasma and its application in ovarian cancer patients
2024, Journal of Pharmaceutical and Biomedical AnalysisPARP inhibitors for prostate cancer
2023, Seminars in Oncology